



がん性疼痛機序の解明と 近大オリジナルの除痛薬開発に向けた合同プロジェクト (講師・吉田健史、yoshida_t@med.kindai.ac.jp)

Research Area

- 1.がん性疼痛に対するオピオイドの効果を予測する臨床研究
- 2.がん性疼痛に対するオピオイドの効果を予測するバイオマーカーの探索
- 3.オピオイドががん患者の生活の質(QOL)に与える影響に関する研究



Matsuoka et al. Onco Report 2012



Recent Activities

- Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study). Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K. BMC Cancer. 2017 Oct 6;17(1):674.
- Matsuoka H, Ishiki H, Iwase S, Koyama A et al. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. BMJ Open. 2017 Aug 28;7(8):e017280
- Matsuoka H, Yoshiuchi K, Koyama A et al. Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine. Int J Behav Med. 2017;24(4):535-541.c